AMS announces US approval for LiquiBand® XL

RNS Number : 6669M
Advanced Medical Solutions Grp PLC
25 May 2022

25 May 2022


Advanced Medical Solutions Group plc

(“AMS” or the “Group”)


US regulatory approval for LiquiBand® XL


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, is pleased to announce that it has received FDA 510(k) approval for LiquiBand® XL, a new device that can close longer wounds than existing LiquiBand® products. The device consists of a surgical mesh which is used to close the wound and LiquiBand® glue which is used to strengthen the closure and prevent infection. Product launch into the US is expected in the third quarter of 2022.


The device has been used successfully on a variety of orthopaedic procedures in multiple territories since its European approval in 2021 and has received very positive feedback in terms ease of use, efficacy and reduced pain and scarring in comparison with other closure methods such as stapling.


The addition of LiquiBand® XL to AMS’ Advanced Wound Closure portfolio is an important step in the development of this franchise. It provides access to a new $60m, long wound sealant market in the US but also increases the overall strength of the LiquiBand® portfolio, as it completes the range of applications available, significantly improving the company’s ability to win new contracts and bundle products.


Chris Meredith, Chief Executive Officer of AMS, commented: “I am delighted to announce the FDA approval of LiquiBand® XL in the US and the addition of this product to our highly successful US LiquiBand® franchise. There is strong demand for the product from hospitals and our distribution partners and we are confident that it will make a significant impact in the market and will play a critical role in strengthening the market share of the entire LiquiBand® franchise.”



– End –



For further information, please contact:


Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations


Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal/ Matthew Cole  


Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Gary Clarence


HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish



About Advanced Medical Solutions Group plc


AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made four acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products and AFS Medical, a specialist distributor of minimally invasive surgical devices based in Austria.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.